Results 1 to 10 of about 123,499 (307)
Polyvalent AIDS vaccines. [PDF]
A major hurdle in the development of a global HIV-1 vaccine is viral diversity. For close to three decades, HIV vaccine development has focused on either the induction of T cell immune responses or antibody responses, and only rarely on both components.
Lu S, Grimes Serrano JM, Wang S.
europepmc +4 more sources
HIV/AIDS Vaccines: 2018. [PDF]
Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I wrote a review, HIV AIDS Vaccines: 2007.
Robinson HL.
europepmc +4 more sources
SARS-CoV-2 has caused the COVID-19 pandemic. B.1.617 variants (including Kappa and Delta) have been transmitted rapidly in India. The transmissibility, pathogenicity, and neutralization characteristics of these variants have received considerable ...
Li Zhang +21 more
doaj +1 more source
HIV-1 pseudoviruses constructed in China regulatory laboratory
To better evaluate HIV-1 vaccines and therapeutics, the National Institutes for Food and Drug Control of China developed a panel of HIV-1 pseudoviruses including 462 viral strains derived from China, covering the majority of contemporaneous subtypes and ...
Jianhui Nie +3 more
doaj +1 more source
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to
Jianhui Nie +17 more
doaj +1 more source
Emerging SARS-CoV-2 variants are the most serious problem for COVID-19 prophylaxis and treatment. To determine whether the SARS-CoV-2 vaccine strain should be updated following variant emergence like seasonal flu vaccine, the changed degree on ...
Jiajing Wu +18 more
doaj +1 more source
Because of its high infectivity in humans and the lack of effective vaccines, Nipah virus is classified as a category C agent and handling has to be performed under biosafety level 4 conditions in non-endemic countries, which has hindered the development
Jianhui Nie +7 more
doaj +1 more source
Pseudovirion-based neutralization assay is considered the gold standard method for evaluating the immune response to human papillomavirus (HPV) vaccines.
Jianhui Nie +3 more
doaj +1 more source
The rise of companies from emerging markets in global health governance: opportunities and challenges [PDF]
The article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies.
ANNE ROEMER-MAHLER +23 more
core +1 more source
Summary: Background: Influenza A (H3N2) virus (A/H3N2) has complex antigenic evolution, resulting in frequent vaccine strain updates. We aimed to evaluate the protective effect of the vaccine strains on the circulating strains from past ten years and ...
Mengyi Zhang +11 more
doaj +1 more source

